Objective:Key genes were screened to analyze molecular mechanisms and their drug targets of endometriosis by applying a bioinformatics approach.Methods:Gene expression profiles of endometriosis and healthy controls we...Objective:Key genes were screened to analyze molecular mechanisms and their drug targets of endometriosis by applying a bioinformatics approach.Methods:Gene expression profiles of endometriosis and healthy controls were obtained from the Gene Expression Omnibus database.Significant differentially expressed genes were screened using the limma package.Correlation pathways were screened by Spearman correlation analysis on the echinoderm microtubule-associated protein-like 4(EML4)and enrichment in endometriosis pathways and estimated by the GSVA package.Immune characteristics were assessed by the“ESTIMATE”R package.Potential regulatory pathways were determined by enrichment analysis.The SWISS-MODE website was used in homology modeling with EML4 and EML4 protein activity was predicted.VarElect was employed in molecular docking for screening potential compound inhibitors targeting endometriosis.Results:Ten endometriosis and 10 normal samples were included.EML4 was significantly upregulated in endometriosis(p<0.05).Thirty significantly correlated pathways involving 18 positive and 12 negative correlations,including GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE and GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES were screened between EML4 and endometriosis.Immunocorrelation analysis showed a significant difference in immune-related pathways in endometriosis and normal samples(p<0.05).In endometriosis,EML4 was associated with T-cell CD4 resting memory,activated mast cells,plasma cells,activated NK cells,M2 macrophages,and follicular helper T cells(p<0.05).Molecular docking identified five potential inhibitors of EML4,and compound DB05104(asimadoline)bound well to EML4 protein to exert its physiological effects.Conclusion:Differential gene expression and immune correlation analyses revealed that EML4 may affect endometriosis through multiple targets and pathways,the mechanism of which involved immune cell activation and infiltration.Molecular docking and dynamics simulation verified DB05104 as a potential inhibitor of EML4 and a powerful target for endometriosis treatment.展开更多
Objective To study the drug effects of ＂Caulis Sargentodoxae Formula＂ which dears away heat and blood clot on experimental endometriosis in rat, and to compare this effect with Danazol＇s effects. Method The model o...Objective To study the drug effects of ＂Caulis Sargentodoxae Formula＂ which dears away heat and blood clot on experimental endometriosis in rat, and to compare this effect with Danazol＇s effects. Method The model of endometriosis rat was induced by transplanting with endometrium surgically The rats were divided into 6 groups randomly： the non-treatment group, the castrate group, Danazol group（80 mg/kg）, ＂Caulis Sargentodoxae Formula＂ group （110 g/kg）, the medium dose group（77.5 g/kg） and the low dose group（55 g/kg）. After 3 weeks＇ treatment, the volume ofendometrium was detected by cutting the rats＇ belly open, drawing the materials from endometrium for tissue section, and doing the quantity analysis of endometrium by semiautomatic image analysis machine.Results There was no significant difference of the endometrium volumes between the low dose group and the non-treatment group（P〉O.05）, other groups＇ endometrium volumes were significantly lower than those of the non-treatment group（P〈0. 05）. And apart from the low dose group, all other groups＇ heights of the endometrium epithelia were significantly lower than that of the non-treatment group（p〈0.01）. Conclusion ＂Caulis Sargentodoxae Formula＂ can refrain the growth of the endometrium, and the effects are better than that of Danazol＇s.展开更多
Objective:To evaluate the efficacy and safety of leuprolide acetate in the treatment of endometriosis. Methods:The patients with endometriosis were randomly divided into leuprolide(n = 75) and control(n=74) groups.The...Objective:To evaluate the efficacy and safety of leuprolide acetate in the treatment of endometriosis. Methods:The patients with endometriosis were randomly divided into leuprolide(n = 75) and control(n=74) groups.They were treated with either sustained-release injection of leuprolide acetate or Enatntone injection(control) for 3 times totally.After treatment,the ovarian mass volume was measured under B ultrasound.The changes in hormone levels of estrodial(E_2),FSH and LH,the pelvic signs,the scores of the patient's subjective symptoms during menstruation and non-menstrual days were observed. Results:The rate of changes in ovarian mass volume had no statistically significant difference between the two groups(P=0.495-0.965).The average reduction of ovarian mass volume was 47.91%in leuprolide group,and 53.51%in the control group 12 weeks after first medication.The distinct improvement rate and improvement rate of total symptom scores during menstruation and non-menstrual days had no significant difference between the two groups.The hormone levels of E_2,FSH and LH were not significantly different between the two groups.The differences in the incidence of adverse reactions were not significant between the two groups. Conclusion:Leuprolide acetate produced by Livzon China is effective and safe in the treatment of endometriosis.展开更多
48 cases of endometriosis were treated with the Neiyi (ectopic endometrium) No. 2 Pills [symbol: see text] 2 [symbol: see text]) composed of fresh Dahuang (Radix et Rhizoma Rhei), Biejia (Carapax Trionycis) and Taoren...48 cases of endometriosis were treated with the Neiyi (ectopic endometrium) No. 2 Pills [symbol: see text] 2 [symbol: see text]) composed of fresh Dahuang (Radix et Rhizoma Rhei), Biejia (Carapax Trionycis) and Taoren Shuang (powdered Semen Persicae). After 3 months of treatment, high effective rates were obtained in menorrhalgia, dyspareunia, proctalgia, hysteromyoma, ovary cyst, and tubercles in the pelvic cavity, with a pregnant rate of as high as 26.7% in sterility. Meanwhile, the levels of plasma PGF2 alpha and PGE2 markedly dropped, while that of 6-keto-PGF1 alpha, beta-EP, and HYP significantly elevated.展开更多
目的采用Meta分析方法系统评价补肾活血中药联合孕三烯酮用于子宫内膜异位症术后治疗的效果和安全性。方法计算机检索中国知网(CNKI)、万方数据、维普网、中国生物医学文献数据库(CBM)、PubMed、Embase和Web of Science等数据库从建库至...目的采用Meta分析方法系统评价补肾活血中药联合孕三烯酮用于子宫内膜异位症术后治疗的效果和安全性。方法计算机检索中国知网(CNKI)、万方数据、维普网、中国生物医学文献数据库(CBM)、PubMed、Embase和Web of Science等数据库从建库至2022年11月有关补肾活血中药联合孕三烯酮用于子宫内膜异位症术后治疗的临床随机对照试验(RCT),制定纳入和排除标准,筛选符合标准的文献。以给予补肾活血中药联合孕三烯酮治疗的患者作为试验组,单纯给予孕三烯酮治疗的患者作为对照组,提取相关资料运用RevMan 5.4.1软件进行Meta分析。结果共纳入7项RCT研究,涉及患者816例。Meta分析结果显示:与对照组相比,试验组的总有效率[比值比(OR)=2.35,95%CI(1.47,3.77),P=0.0004]、妊娠率[OR=2.34,95%CI(1.62,3.38),P<0.00001]显著增高,复发率[OR=0.38,95%CI(0.24,0.59),P<0.0001]、FSH水平[均数差(MD)=-1.53,95%CI(-1.87,-1.20),P<0.00001]、糖类抗原125(CA125)水平[MD=-13.53,95%CI(-16.78,-10.28),P<0.00001]及LH水平[MD=-1.64,95%CI(-1.86,-1.42),P<0.00001]显著降低;两组的不良反应发生率及E 2水平变化无显著性差异(P>0.05)。结论与单纯使用孕三烯酮比较,补肾活血中药联合孕三烯酮用于子宫内膜异位症术后治疗在提高治疗有效率及妊娠率、降低复发率等方面可能更有优势,但因为本研究纳入文献的数量及质量有限,后续仍需要更多高质量的RCT研究进一步验证。展开更多
Endometriosis is a chronic gynecological disorder that affects approximately 10%of women of reproductive age.Most medical treatments used today for endometriosis pain are hormonal therapies,which are not an option for...Endometriosis is a chronic gynecological disorder that affects approximately 10%of women of reproductive age.Most medical treatments used today for endometriosis pain are hormonal therapies,which are not an option for those trying to conceive and are not tolerated by a subset of patients due to side effects.In this article,we offer a comprehensive review of current and investigational medical therapeutic options used to treat endometriosis pain,as well as a symptom-based systematic approach for patients with painful endometriosis.We have also included recommendations for research to enhance the evolution of novel therapeutic options.A thorough literature search was carried out,and the data were synthesized using a synthesis matrix that classifies and categorizes various arguments.展开更多
基金funded by the Role and Mechanism of EML4 in Regulating Oocyte Meiosis and Leading to the Infertility Project(SDFEYJGL2103).
文摘Objective:Key genes were screened to analyze molecular mechanisms and their drug targets of endometriosis by applying a bioinformatics approach.Methods:Gene expression profiles of endometriosis and healthy controls were obtained from the Gene Expression Omnibus database.Significant differentially expressed genes were screened using the limma package.Correlation pathways were screened by Spearman correlation analysis on the echinoderm microtubule-associated protein-like 4(EML4)and enrichment in endometriosis pathways and estimated by the GSVA package.Immune characteristics were assessed by the“ESTIMATE”R package.Potential regulatory pathways were determined by enrichment analysis.The SWISS-MODE website was used in homology modeling with EML4 and EML4 protein activity was predicted.VarElect was employed in molecular docking for screening potential compound inhibitors targeting endometriosis.Results:Ten endometriosis and 10 normal samples were included.EML4 was significantly upregulated in endometriosis(p<0.05).Thirty significantly correlated pathways involving 18 positive and 12 negative correlations,including GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE and GLYCOSPHINGOLIPID_BIOSYNTHESIS_GANGLIO_SERIES were screened between EML4 and endometriosis.Immunocorrelation analysis showed a significant difference in immune-related pathways in endometriosis and normal samples(p<0.05).In endometriosis,EML4 was associated with T-cell CD4 resting memory,activated mast cells,plasma cells,activated NK cells,M2 macrophages,and follicular helper T cells(p<0.05).Molecular docking identified five potential inhibitors of EML4,and compound DB05104(asimadoline)bound well to EML4 protein to exert its physiological effects.Conclusion:Differential gene expression and immune correlation analyses revealed that EML4 may affect endometriosis through multiple targets and pathways,the mechanism of which involved immune cell activation and infiltration.Molecular docking and dynamics simulation verified DB05104 as a potential inhibitor of EML4 and a powerful target for endometriosis treatment.
文摘Objective To study the drug effects of ＂Caulis Sargentodoxae Formula＂ which dears away heat and blood clot on experimental endometriosis in rat, and to compare this effect with Danazol＇s effects. Method The model of endometriosis rat was induced by transplanting with endometrium surgically The rats were divided into 6 groups randomly： the non-treatment group, the castrate group, Danazol group（80 mg/kg）, ＂Caulis Sargentodoxae Formula＂ group （110 g/kg）, the medium dose group（77.5 g/kg） and the low dose group（55 g/kg）. After 3 weeks＇ treatment, the volume ofendometrium was detected by cutting the rats＇ belly open, drawing the materials from endometrium for tissue section, and doing the quantity analysis of endometrium by semiautomatic image analysis machine.Results There was no significant difference of the endometrium volumes between the low dose group and the non-treatment group（P〉O.05）, other groups＇ endometrium volumes were significantly lower than those of the non-treatment group（P〈0. 05）. And apart from the low dose group, all other groups＇ heights of the endometrium epithelia were significantly lower than that of the non-treatment group（p〈0.01）. Conclusion ＂Caulis Sargentodoxae Formula＂ can refrain the growth of the endometrium, and the effects are better than that of Danazol＇s.
文摘Objective:To evaluate the efficacy and safety of leuprolide acetate in the treatment of endometriosis. Methods:The patients with endometriosis were randomly divided into leuprolide(n = 75) and control(n=74) groups.They were treated with either sustained-release injection of leuprolide acetate or Enatntone injection(control) for 3 times totally.After treatment,the ovarian mass volume was measured under B ultrasound.The changes in hormone levels of estrodial(E_2),FSH and LH,the pelvic signs,the scores of the patient's subjective symptoms during menstruation and non-menstrual days were observed. Results:The rate of changes in ovarian mass volume had no statistically significant difference between the two groups(P=0.495-0.965).The average reduction of ovarian mass volume was 47.91%in leuprolide group,and 53.51%in the control group 12 weeks after first medication.The distinct improvement rate and improvement rate of total symptom scores during menstruation and non-menstrual days had no significant difference between the two groups.The hormone levels of E_2,FSH and LH were not significantly different between the two groups.The differences in the incidence of adverse reactions were not significant between the two groups. Conclusion:Leuprolide acetate produced by Livzon China is effective and safe in the treatment of endometriosis.
文摘48 cases of endometriosis were treated with the Neiyi (ectopic endometrium) No. 2 Pills [symbol: see text] 2 [symbol: see text]) composed of fresh Dahuang (Radix et Rhizoma Rhei), Biejia (Carapax Trionycis) and Taoren Shuang (powdered Semen Persicae). After 3 months of treatment, high effective rates were obtained in menorrhalgia, dyspareunia, proctalgia, hysteromyoma, ovary cyst, and tubercles in the pelvic cavity, with a pregnant rate of as high as 26.7% in sterility. Meanwhile, the levels of plasma PGF2 alpha and PGE2 markedly dropped, while that of 6-keto-PGF1 alpha, beta-EP, and HYP significantly elevated.
文摘目的采用Meta分析方法系统评价补肾活血中药联合孕三烯酮用于子宫内膜异位症术后治疗的效果和安全性。方法计算机检索中国知网(CNKI)、万方数据、维普网、中国生物医学文献数据库(CBM)、PubMed、Embase和Web of Science等数据库从建库至2022年11月有关补肾活血中药联合孕三烯酮用于子宫内膜异位症术后治疗的临床随机对照试验(RCT),制定纳入和排除标准,筛选符合标准的文献。以给予补肾活血中药联合孕三烯酮治疗的患者作为试验组,单纯给予孕三烯酮治疗的患者作为对照组,提取相关资料运用RevMan 5.4.1软件进行Meta分析。结果共纳入7项RCT研究,涉及患者816例。Meta分析结果显示:与对照组相比,试验组的总有效率[比值比(OR)=2.35,95%CI(1.47,3.77),P=0.0004]、妊娠率[OR=2.34,95%CI(1.62,3.38),P<0.00001]显著增高,复发率[OR=0.38,95%CI(0.24,0.59),P<0.0001]、FSH水平[均数差(MD)=-1.53,95%CI(-1.87,-1.20),P<0.00001]、糖类抗原125(CA125)水平[MD=-13.53,95%CI(-16.78,-10.28),P<0.00001]及LH水平[MD=-1.64,95%CI(-1.86,-1.42),P<0.00001]显著降低;两组的不良反应发生率及E 2水平变化无显著性差异(P>0.05)。结论与单纯使用孕三烯酮比较,补肾活血中药联合孕三烯酮用于子宫内膜异位症术后治疗在提高治疗有效率及妊娠率、降低复发率等方面可能更有优势,但因为本研究纳入文献的数量及质量有限,后续仍需要更多高质量的RCT研究进一步验证。
文摘Endometriosis is a chronic gynecological disorder that affects approximately 10%of women of reproductive age.Most medical treatments used today for endometriosis pain are hormonal therapies,which are not an option for those trying to conceive and are not tolerated by a subset of patients due to side effects.In this article,we offer a comprehensive review of current and investigational medical therapeutic options used to treat endometriosis pain,as well as a symptom-based systematic approach for patients with painful endometriosis.We have also included recommendations for research to enhance the evolution of novel therapeutic options.A thorough literature search was carried out,and the data were synthesized using a synthesis matrix that classifies and categorizes various arguments.
